Diagnosis and practical management of digoxin toxicity: a narrative review and consensus.
Journal
European journal of emergency medicine : official journal of the European Society for Emergency Medicine
ISSN: 1473-5695
Titre abrégé: Eur J Emerg Med
Pays: England
ID NLM: 9442482
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
30
10
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
There are currently no universally accepted guidelines for the management of digoxin toxicity. In the absence of clinical practice guidelines, a set of consensus recommendations for management of digoxin toxicity in the clinical setting were developed through a modified Delphi approach. The recommendations highlight the importance of early recognition of signs of potentially life-threatening toxicity that requires immediate treatment with digoxin-specific antibodies. The consensus identifies a straightforward approach to dosing immune antibody fragments according to the presence or absence of signs of life-threatening toxicity. Supportive measures and management of specific signs of toxicity are also covered.
Identifiants
pubmed: 37650725
doi: 10.1097/MEJ.0000000000001065
pii: 00063110-202312000-00007
pmc: PMC10599802
doi:
Substances chimiques
Digoxin
73K4184T59
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-401Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al.; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020; 324:2497–2508.
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351:h4451.
Lapostolle F, Borron SW, Verdier C, Arnaud F, Couvreur J, Mégarbane B, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med 2008; 34:1448–1453.
Supervía Caparrós A, Salgado García E, Calpe Perarnau X, Galicia Paredes M, García Gibert L, Córdoba Ruiz F, et al. Immediate and 30 days mortality in digoxin poisoning cases attended in the Hospital Emergency Services of Catalonia, Spain. Emergencias 2019; 31:39–42.
Arbabian H, Lee HM, Graudins A. Elderly patients with suspected chronic digoxin toxicity: a comparison of clinical characteristics of patients receiving and not receiving digoxin-Fab. Emerg Med Australas 2018; 30:242–248.
See I, Shehab N, Kegler SR, Laskar SR, Budnitz DS. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circ Heart Fail 2014; 7:28–34.
Wofford JL, Hickey AR, Ettinger WH, Furberg CD. Lack of age-related differences in the clinical presentation of digoxin toxicity. Arch Intern Med 1992; 152:2261–2264.
Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol 2012; 109:1818–1821.
Cummings ED, Swoboda HD, Digoxin toxicity. In StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2023. https://www.ncbi.nlm.nih.gov/books/NBK470568/ .
Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; 28:483–493.
Hall RJ, Gelbart A, Billingham M, Snidow G, Goldman RH. Effect of chronic potassium depletion on digitalis-induced inotropy and arrhythmias. Cardiovasc Res 1981; 15:98–107.
Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. Br J Clin Pharmacol 1991; 32:717–721.
Arispe N, Diaz JC, Simakova O, Pollard HB. Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels. Proc Natl Acad Sci U S A 2008; 105:2610–2615.
Smith TW. Review of clinical experience with digoxin immune Fab (ovine). Am J Emerg Med 1991; 9(2 Suppl 1):1–6; discussion 33–34.
Protherics UK Limited DigiFab ® . Summary of product characteristics. 2016. https://digifab.health/getmedia/6f38d7ed-1832-4b7d-863a-9c71905e4d02/SmPC_DigiFab_Dec17.pdf .
Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila) 2014; 52:824–836.
Schaeffer TH, Mlynarchek SL, Stanford CF, Delgado J, Holstege CP, Olsen D, et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab: a retrospective study. J Am Osteopath Assoc 2010; 110:587–592.
Thomas E, Tomlinson S, Thomas S, Ward S, Daugherty C, Gallardo E, et al. Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry study. Eur J Hosp Pharm 2022. doi: 10.1136/ejhpharm-2022-003416. [Epub ahead of print].
doi: 10.1136/ejhpharm-2022-003416.
Husby P, Farstad M, Brock-Utne JG, Koller ME, Segadal L, Lund T, et al. Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab). Paediatr Anaesth 2003; 13:541–549.
Zucker AR, Lacina SJ, DasGupta DS, Fozzard HA, Mehlman D, Butler VP Jr, et al. Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child. Pediatrics 1982; 70:468–471.
Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744–1752.
Peters AE, Chiswell K, Hofmann P, Ambrosy A, Fudim M. Characteristics and outcomes of suspected digoxin toxicity and immune Fab treatment over the past two decades - 2000-2020. Am J Cardiol 2022; 183:129–136.
Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17:590–598.
Lalonde RL, Deshpande R, Hamilton PP, McLean WM, Greenway DC. Acceleration of digoxin clearance by activated charcoal. Clin Pharmacol Ther 1985; 37:367–371.
Park GD, Goldberg MJ, Spector R, Johnson GF, Feldman RD, Quee CK, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm 1985; 19:937–941.
Hoegberg LCG, Shepherd G, Wood DM, Johnson J, Hoffman RS, Caravati EM, et al. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clin Toxicol (Phila) 2021; 59:1196–1227.
Liisanantti J, Kaukoranta P, Martikainen M, Ala-Kokko T. Aspiration pneumonia following severe self-poisoning. Resuscitation 2003; 56:49–53.
Mowry JB, Burdmann EA, Anseeuw K, Ayoub P, Ghannoum M, Hoffman RS, et al.; EXTRIP Workgroup. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila) 2016; 54:103–114.
Pincus M. Management of digoxin toxicity. Aust Prescr 2016; 39:18–20.
Navab F, Honey M. Self-poisoning with digoxin: successful treatment with atropine. Br Med J 1967; 3:660–661.
Reiffel JA, Bigger JT Jr, Cramer M. Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol 1979; 43:983–989.
Cohen L, Kitzes R. Magnesium sulfate and digitalis-toxic arrhythmias. JAMA 1983; 249:2808–2810.
Freedman RA, Swerdlow CD, Echt DS, Winkle RA, Soderholm-Difatte V, Mason JW. Facilitation of ventricular tachyarrhythmia induction by isoproterenol. Am J Cardiol 1984; 54:765–770.
Holmén J, Hollenberg J, Claesson A, Herrera MJ, Azeli Y, Herlitz J, et al. Survival in ventricular fibrillation with emphasis on the number of defibrillations in relation to other factors at resuscitation. Resuscitation 2017; 113:33–38.
Straznitskas AD, Wong S, Kupchik N, Carlbom D. Secondary ventricular fibrillation or pulseless ventricular tachycardia during cardiac arrest and epinephrine dosing. Am J Crit Care 2015; 24:e22–e27.
Taboulet P, Baud FJ, Bismuth C, Vicaut E. Acute digitalis intoxication: is pacing still appropriate? J Toxicol Clin Toxicol 1993; 31:261–273.
Bismuth C, Motte G, Conso F, Chauvin M, Gaultier M. Acute digitoxin intoxication treated by intracardiac pacemaker: experience in sixty-eight patients. Clin Toxicol 1977; 10:443–456.
Chan BS, Isbister GK, O’Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol (Phila) 2016; 54:488–494.
Chan BS, Isbister GK, Page CB, Isoardi KZ, Chiew AL, Kirby KA, et al. Clinical outcomes from early use of digoxin-specific antibodies versus observation in chronic digoxin poisoning (ATOM-4). Clin Toxicol (Phila) 2019; 57:638–643.
Bilbault P, Oubaassine R, Rahmani H, Lavaux T, Castelain V, Sauder P, et al. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emerg Med 2009; 16:145–149.
Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev 2004; 23:135–143.